Celularity Inc.
CELU evidence brief
What we can confirm
- BioSniper Score:
- 7.8 / 10
- Market Cap:
- $44.3M
What it means
What to watch
Prepared research question
What matters most for CELU—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CELU
Celularity Inc. (CELU) is a regenerative and cellular medicine company developing placental-derived cellular therapies, with a focus on longevity and age-related disease, while managing a negative equity position and limited cash reserves.
Key risk: Negative equity and high deficit
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$44.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Mar 31, 2026.
Tracking 6 clinical trials for Celularity Inc..
Celularity Inc. (CELU) is a regenerative and cellular medicine company developing placental-derived cellular therapies, with a focus on longevity and age-related disease, while managing a negative equity position and limited cash reserves.
- Cash & equivalents of $0.4M as of 2026-03-31 [sec]
- Total revenue of $3.8M and net income of $0.9M for the period ended 2026-03-31 [sec]
- Shareholders' equity of -$35.3M as of 2026-03-31 [sec]
- Accumulated deficit of $990.6M as of 2026-03-31 [sec_mda]
- Announced a recapitalization plan of up to $28 million in September 2026 [news]
What works
- Celularity has secured a recapitalization plan of up to $28 million, including over $10 million initial financing, to support commercial execution and manufacturing expansion [news]
- The company anticipates positive monthly operating cash flow by the end of Q1 2027 [news]
- Celularity is pursuing a scalable pathway for placental-derived cell therapies under a new Florida law, potentially expanding market access [news]
- The company has a strategic partnership with Fontaine Vitale in the Asia-Pacific region, expected to open in Q1 2027, representing a new revenue opportunity [news]
What to weigh
- Celularity has a negative shareholders' equity of -$35.3M and an accumulated deficit of $990.6M as of 2026-03-31 [sec] [sec_mda]
- Cash and cash equivalents are only $0.4M as of 2026-03-31, indicating very limited liquidity [sec_mda]
- The company's cellular therapy candidates are investigational and have not received FDA approval; safety and effectiveness are not established [sec_mda]
- Celularity expects to incur significant commercialization expenses if regulatory approval is obtained, and current commercialization efforts are limited to biobanking and degenerative disease businesses [sec_mda]
From the filings
Quoted directly from source documents.
Cash position is very low
“As of March 31, 2026, we had cash and cash equivalents of $0.4 million”
SEC MD&A · September 29, 2026
Company has a large accumulated deficit
“accumulated deficit of $990.6 million”
SEC MD&A · September 29, 2026
Recapitalization plan announced
“Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements”
News · September 24, 2026
Cellular therapy candidates are not FDA-approved
“Our cellular therapy candidates are investigational and have not been approved by the U.S. Food and Drug Administration. Their safety and effectiveness for the proposed indications have not been established.”
SEC MD&A · September 29, 2026
Catalyst timeline
- 2020-09-02 · Phase2_Start: A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 — This trial was initiated in 2020; no recent updates on status are provided in the chunks.
- 2021-09-01 · Phase2_Start: A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type Glioblastoma — This trial was initiated in 2021; no recent updates on status are provided in the chunks.
Risks & what to watch (4)›
Key risks
- Negative equity and high deficit — Shareholders' equity is -$35.3M and accumulated deficit is $990.6M as of 2026-03-31 [sec] [sec_mda]
- Very low cash reserves — Cash and equivalents are only $0.4M as of 2026-03-31, posing liquidity risk [sec_mda]
- No FDA-approved products — All cellular therapy candidates are investigational and not approved; safety/efficacy unproven [sec_mda]
- Dependence on financing and partnerships — Company relies on equity/debt financings and collaborations to fund operations; cash flow from operations not yet positive [sec_mda]
What to watch
- Achievement of positive monthly operating cash flow by end of Q1 2027, as anticipated [news]
- Opening of Fontaine Vitale in Q1 2027 as a strategic partner in Asia-Pacific [news]
- Progress of cellular therapy candidates through clinical trials and any regulatory milestones [sec_mda]
- Execution of the recapitalization plan and its impact on liquidity and operations [news]
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run Celularity Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Celularity Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Profitable (positive operating cash flow)
OCF $1M · Net income $874K
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
38
Total value held
$2.9M
| Holder | Shares | Value |
|---|---|---|
| c v starr & co inc | 764,069 | $1.0M |
| vanguard capital management llc | 621,105 | $826K |
| geode capital management, llc | 191,076 | $254K |
| blackrock, inc. | 127,501 | $170K |
| vanguard fiduciary trust co | 79,874 | $106K |
| state street corp | 57,830 | $77K |
| valmark advisers, inc. | 49,983 | $66K |
| northern trust corp | 44,163 | $59K |
| hb wealth management, llc | 40,415 | $54K |
| biltmore family office, llc | 35,000 | $47K |
Showing top 10 of 38 institutional holders of Celularity Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 4.1%
- Days to cover
- 8.0
- Shares short
- 275,407
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CELU short interestGovernance
Frequently asked questions
What is the AI investment thesis for Celularity Inc.?
Celularity Inc. (CELU) is a regenerative and cellular medicine company developing placental-derived cellular therapies, with a focus on longevity and age-related disease, while managing a negative equity position and limited cash reserves.
Who is the CEO of Celularity Inc.?
Dr. Robert Joseph Hariri M.D., Ph.D. is the chief executive officer of Celularity Inc. (CELU).
Where is Celularity Inc. headquartered?
Celularity Inc. (CELU) is headquartered in Florham Park, NJ, United States.
What therapeutic areas does Celularity Inc. focus on?
Celularity Inc. develops therapies across Oncology, Immunology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.